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Colorectal cancer is the fourth most common cancer
and the second leading cause of cancer death. Transfor-
mation begins with activation of Wnt signaling through
mutations in APC (80%) or its degradation target
b-catenin (15%), producing a gain-of-function in TCF-
dependent nuclear transcription underlying epithelial
dysfunction and tumorigenesis. While a role for APC
and b-catenin in colorectal cancer is well-established,
steps leading from gene mutation to tumorigenesis, and
their reversibility, remain incompletely defined. Guanylin
is the paracrine hormone in colorectum for the receptor
GUCY2C. This hormone is the most commonly lost
gene product in colorectal cancer, and its universal
suppression and associated silencing of GUCY2C at the
earliest step in neoplasia contributes to tumorigenesis in
a mechanism that is conserved across species. GUCY2C
regulates homeostatic mechanisms organizing the intest-
inal crypt-surface axis, and its silencing through guany-
lin suppression drives hyperproliferation, DNA damage,
metabolic reprogramming and desmoplasia contributing
to tumorigenesis. Beyond this dysregulation of homeo-
static mechanisms contributing to transformation, we
recently discovered that guanylin suppression is required
for tumorigenesis induced by mutant APC-b-catenin,
reflecting a role for GUCY2C in b-catenin degradation
that blocks tumorigenesis. Thus, inactivation of APC, or
activation of b-catenin, induces TCF-dependent elimina-
tion of guanylin transcription and translation in human
intestinal cells in vitro and in conditional genetic mouse
models in vivo. Conversely, activation of GUCY2C induces
cGMP protein kinase-dependent elimination of wild type
or mutant b-catenin by amplifying proteosomal degrada-
tion, even in the context of mutations which inactivate the
APC degradation complex. Importantly, enforced genetic
expression of guanylin in intestinal epithelial cells comple-
tely eliminated tumorigenesis in all mouse models of col-
orectal cancer examined. These observations reveal a
pathophysiologic model in which mutant APC-b-catenin
signaling eliminates guanylin expression as an obligatory
step in tumorigenesis. In turn, silencing GUCY2C reversi-
bly disrupts epithelial homeostatic processes corrupted in
tumorigenesis, and removes an essential block to transfor-
mation, creating a circuit which amplifies mutant APC-b-
catenin signaling. These studies shift the prevailing para-
digm for colorectal tumorigenesis from an irreversible
oncogenomic mechanism to a reversible functional
mechanism whose reconstitution abrogates those muta-
tional defects. Indeed, they define a novel molecular path-
way that is obligatory for tumorigenesis, to which the
transformation process is addicted. In that context, they
highlight how this addiction creates a unique disease-spe-
cific vulnerability that can be leveraged to eliminate
tumorigenesis by GUCY2C hormone replacement. We
have translated these observations to an NCI-funded
clinical program exploring the utility of oral GUCY2C
ligands to prevent colorectal cancer.
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